Dostarlimab Medicine 04 June 2026 Extended indication Dostarlimab in combination with carboplatin-paclitaxel followed by maintenance dostarlimab plus niraparib for treatment of recurrent or primary advanced Endometrial cancer in adults and elderly. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Dostarlimab Domain Oncology Reason of inclusion Indication extension IND Main indication Oncology other Extended indication Dostarlimab in combination with carboplatin-paclitaxel followed by maintenance dostarlimab plus niraparib for treatment of recurrent or primary advanced Endometrial cancer in adults and elderly. Current proprietary name Already available biosimilars / generics Proprietary name Jemperli Manufacturer GSK Portfolio holder GSK Mechanism of action PD-1 / PD-L1 inhibitor Route of administration Intravenous Therapeutical formulation Infusion fluid Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Particularity ATMP Submission date June 2026 Expected Registration December 2026 Orphan drug Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Tijdslijn op basis van IHSI-inschatting. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation De studieresultaten zijn nog niet bekend. Duration of treatment Frequency of administration Dosage per administration References NCT03981796 (RUBY) Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References (1) NKR 2021 (2) Huijgens AN, Mertens HJ. Factors predicting recurrent endometrial cancer. Facts Views Vis Obgyn. 2013;5(3):179-86. PMID: 24753943; PMCID: PMC3987371. Additional remarks Er waren in 2021 in totaal 2.221 patiënten met een endometriumcarcinoom. De verdeling van het aantal patiënten per FIGO stadium is 80,9% voor stadium 1, 4,8% stadium 2, 11,5% stadium 3 en 2,9% stadium 4. Patiënten met een gevorderd stadium van endometriumcarcinoom (stadium 3 en 4) komen in aanmerking voor systemische therapie. Expected cost per patient per year Cost € 45,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References medicijnkosten.nl; IHSI Additional remarks De lijstprijs voor één 10ml flacon dostarlimab (Jemperli) (50mg/ml) is €3.710 (exclusief BTW). De lijstprijs per 100mg capsule niraparib (Zejula) is €92,43 (exclusief BTW). Op basis van IHSI-inschatting, afgeleid van de mediane kosten van dezelfde ATC-klasse (L01FF - PDL1 remmers) geneesmiddelen in Nederland, komen de kosten per patiënt per jaar uit op ongeveer €45.000. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks